January 29, 2026- Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter and Full Year 2025 Highlights
- Fourth quarter revenue grew 7% to $12.21 billion.
- Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21.
- Fourth quarter adjusted EPS grew 8% to $6.57.
- Full year revenue grew 4% to $44.56 billion.
- Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74.
- Full year adjusted EPS grew 5% to $22.87.
- Advanced proven growth strategy by launching a range of high-impact, innovative new products in 2025. Highlights include the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer, Thermo Scientific™ Krios™ 5 Cryo-TEM, Thermo Scientific™ Vulcan™ Automated Lab, and the bench-scale Thermo Scientific™ 5L DynaDrive™ Single-Use Bioreactor. During the fourth quarter we launched the Thermo Scientific™ Helios™ MX1 Plasma Focused Ion Beam Scanning Electron Microscope, a fully automated semiconductor analysis system designed to accelerate time-to-data for yield ramp and fab process control, and we received FDA approval for the Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic for HYRNUO™, Bayer’s targeted therapy for patients with HER2-mutated non-small cell lung cancer, as well as U.S. 510(k) clearance for the EXENT System, a first-of-its-kind automated platform to aid in the diagnosis of multiple myeloma.